

Optimizing specimen handling for precision medicine applications

27.09.24 Tea Pemovska, PhD





I have no disclosures

Contents

01 Introduction

02 Precision Medicine & Functional Precision Medicine

03 Session objectives


04 Biospecimens

05 Specimen collection

3 Optimizing specimen handling for precision medicine applications

06 Specimen storage 07 Specimen handling 08 Specimen transport 09 Analytical factors **10** EXALT-2 trial case study seha Sf(PM)

A form of medicine that uses information about person's genes or proteins



4 Optimizing specimen handling for precision medicine applications

- nowadays common practice to collect and store numerous different biological samples
 - healthy donors and patients
 - biobanks
 - collection, processing, preservation, and storage
 - assuring high-quality samples and data
 - ethical and legal compliance
 - transparent and efficient access procedures
- insight into the molecular mechanisms underlying individual diseases
 - can only be obtained from investigation of human biological samples
 Can only be obtained from investigation of human biological samples


Why precision medicine?

Personalized therapy can reduce healthcare costs in the long run

- by reducing
 - ineffective treatments
 - side effects
 - low quality of life
 - hospitalizations


TRADITIONAL MEDICINE: SAME TREATMENT FOR ALL

Cancer patients with e.g. colon cancer receive the same therapy even though they have different biomarkers



INNOVATIVE MEDICINE: PERSONALISED MEDICINE

Cancer patients with e.g. colon cancer receive a personalised therapy based on their biomarkers




Rapid advances in molecular technology

Yielded clinical-grade tests

- permit deep interrogation of tumor biology
- identification of complex and unique molecular features
- provide personalized treatment to patients


Precision medicine

- exploited next-generation sequencing
- customization of patient therapy
- successfully transformed the outlook for several fatal cancers
- Enabled a revolution in clinical trial design





Role of biobanks in personalized



Annaratone et al. Virchows Archiv 2021

7

seha Sf(PM)



Sample collection and preservation

Patient Consent and Information

Obtaining informed consent from patients is paramount. Patients must understand the purpose of sample collection, the potential risks and benefits, and the use of their data. Clear communication and detailed documentation are essential.

Appropriate Collection Methods

Proper collection methods are crucial to minimize contamination and maintain sample integrity. Standardized procedures, trained personnel, and appropriate collection tools should be employed to ensure consistent and accurate sample collection.

Preservation and Storage

Preserving and storing samples correctly is vital for maintaining their quality and stability over time. This involves using appropriate storage conditions, including temperature, humidity, and light exposure, to prevent degradation and ensure reliable analysis.

Functional precision medicine (FPM) in oncology

Patient's tumor cells are directly perturbed with drugs

- generates dynamic, functional data
 - encompassing key vulnerabilities and dependencies
 - agnostic with respect to disease mechanisms
 - rely on direct measurements of cellular functions

Help us to read the cancer genome


• functional profiles can link to genetic alteration patterns



• potential for immediate translation of results, personalized treatment recommendation

9

"put drugs on cancer cells and see if they work"



FPM is not a new concept

Chemosensitivity testing began more than 50 years ago


• most curative cytotoxic regimens used today derived from these crude assays

Two editorials in NEJM in 1983 and position papers by ASCO cast doubt on the utility

- personalizing cancer care
 - lack of tumor cells surviving culture conditions
 - unsophisticated culture conditions
 - uninformative assays
 - drug armamentarium relatively small
 - lack of prospective data demonstrating utility


Restored interest in the last decade

- increased in biological knowledge
- available technology
- number of drugs available



Challenges of FPM


- Requirement of viable tissue
- Requirement of sufficient tumor cell yields
 - highly suitable for hematological cancers
- Limit the presence of unfavorable areas (e.g., necrosis, fibrosis, blood clots)
- Adapting routine sample handling in hospitals
 - preserve viability
 - sample integrity
 - still enable standard diagnostic procedures
- Proper specimen sampling
 - capturing specimen heterogeneity
 - avoidance of selection bias (overly or underly abundant cell populations)



Session scope and objectives

to understand best practices in shipping, storage, and quality control of patient specimens

importance of quality control in ensuring specimen integrity and reliability of results




Biospecimens

- Materials obtained from the human body
 - used to diagnose and analyze disease (e.g., cancer)
 - tissue
 - blood
 - plasma
 - other biological fluids




- High-quality biospecimens are defined as those whose biology most closely resembles the biology of the biospecimen prior to its removal from the human research participant
- Once the biospecimen is collected (and sometimes before its removal)
 - the biospecimen may begin to take on new characteristics
 - changes to the biospecimen's environment
 - that may occur during a surgical or collection procedure
 - > inaccurate determinations of molecular and physical biospecimen characteristics



Lifecycle of biospecimens

- The life cycle stages of biosamples can vary
 - type of sample
 - intended use
 - critical
 - maintaining their integrity
 - quality
 - usefulness for future research

	Ti	me 0					
The s	pecimen i	s biologio	cally viable	e			
				R			
Patient	Medical/ Surgical Procedures	Acquisition	Handling/ Processing	Storage	Distribution	Scientific Analysis	Restocking Unused Sample
Pre-acquisition Post-acquisition					Au	dubon bio	oscience






Table I. The life cycle steps of biosamples for personalized medicine.				
Step	Role	Reference		
Collection	Biosamples are collected from donors or patients through various methods, such as biopsy, blood draw, or saliva swab, in a sterile and consistent manner to avoid contamination or degradation	[4,19,26]		
Processing	Processed to extract specific components or prepare them for analysis; separating cells from tissues, isolating DNA or RNA, or freezing the samples for long-term storage.	[4,26]		
Storage	Can be stored for various periods (ranging from a few hours to several decades). Proper storage conditions are critical to ensure sample integrity and avoid degradation or contamination. Depending on the sample type and storage duration, different storage methods, such as refrigeration, freezing, or cryopreservation, may be used	[4,19,26]		
Analysis	Biosamples are typically analyzed to answer research questions or diagnose medical conditions. This may involve various techniques, such as microscopy, genomics, proteomics, or metabolomics, depending on the specific research question and sample type are some specific requirements related to quality control for samples.	[4,9,26]		
Disposal/ Restocking	Once the analysis is complete, biosamples may be disposed of in a proper and ethical manner. This may involve autoclaving, incineration, or chemical treatment, depending on the sample type and any associated hazards.	[4,9,26]		

Policiuc et al, Med Pharm Rep 2023



The use of human biospecimens for personalized medicine in oncology

- Use of high-quality samples
 - strict ethical
 - procedural guidelines
- Standardized protocols is paramount
 - consistent processing of samples across different studies
 - same equipment, reagents, and procedures
 - minimize variability
 - increase reproducibility
- Speed of processing also important
 - prevent degradation
 - maintain the integrity of biological molecules (e.g., DNA, RNA, proteins)

- Quality control measures
 - quantity
 - quality
 - free from contamination
 - other factors affecting reproducibility





Specimen integrity

- dependent on accurate pre-analytical processes
 - patient preparation
 - specimen collection
 - handling
 - transportation
 - processing
 - analysis
 - storage
- Improper collection and handling
 - erroneous results
 - compromise data translatability
 - care of the patient



Processing variability

Factors affecting the biospecimens during the processing steps

- Type of processing method used
- Time between collection and processing
- Conditions during processing
 - Can also lead to changes in the biospecimen composition
 - impacting the accuracy and reproducibility of data generated
- Post-analytical processing
 - factors affecting data generated after the biospecimens have been analyzed
 - data analysis methods
 - data interpretation
 - lead to differences in the results obtained
 - impacting the reproducibility of data generated



Preanalytical variables

Patient-Related factors

Individual factors like age, gender, diet, medications, and overall health status can influence the composition and integrity of specimens. Understanding these factors helps in interpreting results accurately. Time of Day and Collection Procedure

The time of day can affect certain biomarkers, such as hormones. The method of collection, whether it involves fasting or specific protocols, can also impact specimen integrity.

Transportation and Handling

How specimens are transported and handled during transit can influence their quality. Timely transportation, proper temperature control, and adherence to established protocols are essential.





Specimen collection

Appropriate Collection Techniques

Using the correct tools and procedures for collecting specimens is critical. For example, using sterile needles and tubes for blood collection minimizes contamination risks, while tissue biopsies should be performed with precision to avoid damage.

Timely Processing

Specimens should be processed as soon as possible after collection to minimize degradation. This involves steps like centrifugation for blood samples or immediate fixation for tissue samples. The delay in processing can lead to changes in cellular structure and composition.

Proper Labeling and Storage

Accurate labeling of specimens is crucial to prevent mix-ups and ensure traceability. Proper storage conditions, such as refrigeration or freezing, are essential to maintain specimen integrity over time.

Environmental Factors


Exposure to extreme temperatures, humidity, or light can negatively impact specimens. Proper packaging and transport conditions $\mathcal{S} \in \mathcal{A} \mathcal{S} f(\mathsf{PM})$ should be implemented to protect them from environmental fluctuations.

Specimen collection

Patient results are only as good as the specimen collected

- Requirements for collection and handling must be followed
- Critical that adequate volumes are collected
- Avoid the use of expired collection tubes
- Collect in the correct order of draw (blood samples)
 - inverted gently to ensure proper mixing of additive or anticoagulant
 - prevent contamination with anticoagulants and inaccurate results
- Tissue samples histologically reviewed by histopathologist
- Specimen labeling
 - unique identifiers
- Preservation method
 - as quick as possible
 - suited for expected and unforeseen future use
 - preventing confounders influencing molecular stability and degradation





Specimen Preservation and Storage

Fixation

For tissue specimens, fixation is often used to preserve cellular structure and prevent degradation. Common fixatives include formalin, alcohol, or special solutions depending on the type of tissue.

Freezing

4.1.1.4

Freezing is used for preserving samples at very low temperatures, often using liquid nitrogen or ultra-low freezers. This helps to slow down or stop biological processes and maintain the integrity of specimens for extended periods.

Storage Conditions

Specimens are stored in specific conditions based on their type and intended use. These conditions include appropriate temperatures, humidity levels, and light exposure, all crucial for maintaining their integrity.

Long-Term Stability

Long-term storage strategies for specimens, such as cryopreservation or lyophilization (freeze-drying), aim to preserve their $\mathcal{S} = \mathcal{O} = \mathcal{O} + \mathcal{O} +$

Biospecimen storage

- Storage in a stabilized state
- Avoiding freeze-thaw cycles
- Appropriate storage temperature
 - biospecimen type
 - downstream application
 - length of storage



- use of appropriate storage containers for storage temperature
- Optimal volume
 - prevent sample loss
 - minimize costs
 - collection
 - storage
 - retrieval


screw-cap cryovials may be used for long-term, lowtemperature storage glass vials or vials with popup tops are unsuitable for long-term storage snap-frozen biospecimens should be wrapped in aluminum foil or placed in commercial storage containers to minimize desiccation formalin-fixed, paraffin-embedded tissue should be stored as a block and not sliced until analysis is imminent slide-mounted cut sections must undergo thorough dehydration and processing prior to storage

24 Optimizing specimen handling for precision medicine applications

Specimen Handling

- Every attempt to optimize specimen handling
 - minimize molecular changes from processing activities
 - e.g., cold ischemia time
 - temperature
 - processing time
 - size and volume of biospecimen
 - number of aliquots
 - rate at which samples are cooled to storage temperature
 - avoiding freeze-thaw cycles

The quality of assays can be impacted by inconsistent sample handling



Contamination and degradation

Biological Contamination

From bacteria, fungi, or viruses can alter specimen integrity. Sterile techniques and proper handling are essential to minimize these risks.

Chemical Contamination


Exposure to chemicals, such as cleaning agents or solvents, can damage specimens. Avoiding cross-contamination is crucial.

Degradation Over Time

Even under optimal storage conditions, biological specimens undergo natural degradation processes involving enzyme activity, oxidation, or the breakdown of cellular structures.

DNA Degradation

DNA is particularly susceptible to degradation, especially in the presence of enzymes like DNases. Proper handling and storage are essential to minimize DNA breakdown.



Automation and standardization

Automated Sample Processing


Automated systems can significantly improve efficiency, consistency, and accuracy in sample handling. Robotic systems can perform tasks such as sample extraction, preparation, and analysis, reducing manual error and increasing throughput.

Standardized Protocols

Implementing standardized protocols for sample handling ensures consistency across different laboratories and research groups. This reduces variability and enhances the reproducibility of results.

Data Integration

Integrating data from different sources, such as sample tracking systems, laboratory instruments, and clinical databases, can provide a comprehensive view of the entire sample lifecycle, enhancing data analysis and interpretation.



Specimen Transport

Chain of Custody

Establishing a chain of custody is crucial for maintaining sample traceability and ensuring sample integrity. This involves meticulously documenting the handling and movement of samples from collection to analysis, ensuring accountability and preventing misidentification.

Transport Conditions

2

3

Maintaining appropriate temperature and humidity controls during transport is crucial for preserving sample quality. Specialized containers, cold-chain systems, and tracking devices are used to ensure samples remain stable and viable.


Sample Identification and Labeling

Accurate sample identification and labeling are essential for preventing misidentification and ensuring correct data association. Clear, legible labels with unique identifiers should be attached to each sample throughout the handling process.

Key considerations – sample shipment

shipping approptime		climate
insulation prevent	temperature	dry ice
temp fluctuations		
mode of transport	regulations	sample type / intended use

- enough refrigerant should be included to allow for at least a 24-hour delay in transport
- temperature-sensitive material should be handled by a courier
- resources to replenish the refrigerartence artence artenc




Packaging

• Primary Container:

• Use leak-proof, sterile containers for collecting blood or bone marrow samples. Ensure that the container is securely closed.

• Secondary Container:

- Place the primary container in a secondary, leak-proof container with enough absorbent material to contain any potential leaks.
- Tertiary Packaging:
 - Use a rigid, puncture-resistant outer container for added protection. This is often a foam or insulated box to maintain temperature control.
- Cushioning:
 - Ensure that the samples are well-cushioned to prevent movement and breakage during transit.



Analytical factors

- Introducing pre-analytical variables
 - differences in the performance of a particular assay
- To minimize errors
 - Use of validated assays, where possible
 - Use of SOPs by well-trained staff
 - Lot uniformity of reagents
 - Inclusion of appropriate type and number of quality control (reference) samples
 - Randomization, when possible
 - Standardized methods for documenting and interpreting test results





Impact of Specimen Integrity on Precision Medicine



Accurate Diagnosis

Degraded or contaminated specimens can lead to inaccurate diagnostic results, potentially delaying or misdirecting treatment.

Personalized Treatment Selection

Reliable information from specimens is crucial for choosing the most effective and targeted therapies for individual patients.

Scientific Research

Maintaining specimen integrity ensures the validity and reliability of research findings, impacting the advancement of precision medicine and therapeutic strategies.



Improved Patient Outcomes

By ensuring accurate and reliable data from specimens, precision medicine aims to optimize treatment outcomes, reduce adverse effects, and improve patient well-being. $\& ha \ Sf(PM)$



Challenges and Future Directions

Sample Heterogeneity

Biological samples exhibit considerable variability, presenting challenges for standardization and analysis. Developments in biobanking and sample characterization are needed to address this heterogeneity.

Data Security and Privacy

Protecting sensitive patient information is critical. Robust data security measures and ethical guidelines are essential to ensure responsible use and prevent unauthorized access to patient data. 3

Emerging Technologies

Advances in technologies such as liquid biopsies, microfluidic devices, and artificial intelligence are transforming specimen handling. These innovations offer potential for increased efficiency, precision, and personalized medicine. & ha Sf(PM)

Quality Control and Assurance

Control Measures

Visual Inspection

Analytical Validation

Audits and Reviews

Temperature Monitoring

Purpose

Specimen Identification and Tracking

Ensure accurate labeling and traceability throughout the process.

Maintain optimal storage and transport conditions.

> Identify any visible signs of degradation or contamination.

Verify the accuracy and reliability of analytical techniques.

Assess compliance with established protocols and identify areas for improvement.

Speccinnned Quality Control



Conclussion

Maintaining specimen integrity is a critical aspect of precision medicine, ensuring accurate and reliable data for diagnosis, prognosis, and treatment selection. By understanding the factors that can affect specimen quality, implementing appropriate procedures, and utilizing emerging technologies, we can enhance the accuracy and effectiveness of precision medicine, ultimately improving patient outcomes and advancing personalized healthcare.



Case studies



Cancer Treatment


Personalized cancer treatments based on tumor genomic and functional profiling have led to significant improvements in patient outcomes, showcasing the power of precision medicine.

- EXALT-2 study sample handling procedures
- Alice Soragni's organoid generation from solid tumor biopsies



EXALT 2.0

Comprehensive genomic profiling and next generation drug screening for patients with aggressive haematological malignancies: next generation personalized hematology



* If no treatable target is identified or if no report is available in Arm A or B, a cross-over between group A and B is possible. If no target is found at all, the patient will be treated according to the physicians' choice.

Centers

Medical University Vienna Innsbruck University Hospital Medical University Graz Keppler University Linz Medical University Salzburg

Start Q2 2020

Sponsor MUW, Roche


PI Staber, Kazianka



Protocol overview – Eligibility criteria

Inclusion	Exclusion		
r/r aggressive hematological malignancy	2 nd malignancy*		
≥ 2 prior lines of therapy**	participation in another clinical trial		
response to previous therapy < 1 year	pregnancy		
ECOG ≤ 2	ECOG > 2		
antitumor therapy medically feasible	Hodgkin's lymphoma		
real-time biopsy feasible	age < 18 years		

* diagnosed < 1 year prior to study inclusion (except for localized squamous cell carcinoma and basal cell carcinoma of the skin; ** or 1 prior therapy and no standard of care available




Protocol overview – Efficacy endpoints


Individual PFS benefit


PFS ratio (PFS on A or B or C / PFS of most prior therapy) ≥ 1.3 Average Ratio of PFS on A or B or C treatment

Overall response rate (ORR) Number of treatable targets




Overall survival (OS) Successful bridging to HSCT for eligible patients Time to result informed consent signed biopsy taken availability of results randomization board decision start of treatment







Vivi-bank Collaboration with Institute of Pathology





OUNDATION**ONE®HEME**

Specimen Instructions

Fresh Specimens (Peripheral Whole Blood or Bone Marrow Aspirate)


Lesional tissue should constitute >20% of nucleated elements for optimal analysis.

PERIPHERAL WHOLE BLOOD

- 1 Fill the EDTA (lavender-top) tube with blood (for submission, not for waste).
- 2 Collect 2.5mL blood in the PAXgene Blood RNA Tube (see separate instruction sheet for additional details).
 - a. Ensure that tube is at room temperature.
 - b. Always ensure that the PAXgene tube is the last tube drawn in the phlebotomy procedure.
- **3** Confirm that both the EDTA and PAXgene tubes are labelled with the specimen type (e.g., PB = peripheral blood), date of collection, and two unique patient identifiers (labels included in kit).
- 4 Ship BOTH tubes at ambient temperature, confirming expedited / overnight shipping with courier to guarantee next day delivery (see shipping instructions below for further details).

BONE MARROW ASPIRATE

- Collect 2.5 mL bone marrow aspirate in one EDTA (lavender-top) tube.
- 2 Confirm tube is labelled with the specimen type (e.g., BMA = bone marrow aspirate), date of collection, and two unique patient identifiers (labels included in kit).
- 3 Ship at ambient temperature, confirming expedited / overnight shipping with courier to guarantee next day delivery (see shipping instructions below for further details).





OUNDATION**ONE®HEME**

Specimen Instructions

Fresh Specimens (Peripheral Whole Blood or Bone Marrow Aspirate)

Additional Submission Requirements

- 1. Peripheral blood and bone marrow aspirate must be received the day after collection for optimal analysis, as sensitivity of detection may degrade with time. Please ensure specimens are shipped from Monday through Thursday, at ambient temperature, confirming expedited/overnight shipping with courier to guarantee next day delivery. Specimens shipped on Friday can only be received before 14.00 CET on Saturday.
- 2. Neoplastic/lesional cells must constitute at least 20% of nucleated cellular elements (tumour content will be determined based upon cytomorphologic review in conjunction with other supporting laboratory results when appropriate).
- 3. Specimens should NOT be frozen prior to submission.
- 4. Please submit concurrent or recent laboratory test results (e.g., CBC/differential, flow cytometry results, final bone marrow pathology report) if available.


NUCLEIC ACID TYPE	SUBMISSION FORMAT	CONCENTRATION*	VOLUME	SHIPPING INSTRUCTIONS
DNA	Nuclease-free water	Picogreen: ≥3.5 ng/μl UV: ≥10 ng/μl	≥60 µl	Ship overnight, frozen on dry ice
RNA	Nuclease-free water	Ribogreen: ≥20 ng/µl	≥30 µl	Ship overnight, frozen on dry ice

Extracted Nucleic Acid Submission Requirements


Please specify concentration on requisition form

PB/BM sample preparation for drug screening application

- Combine PB/BM from at least two heparin tubes
- Perform Ficoll-density gradient mononuclear cell isolation
- Centrifugation 300 g for 30 min at RT (brake should be turned off)
- Draw off the upper layer containing plasma and platelets using a sterile pipette, leaving the mononuclear cell layer undisturbed at the interface
- Transfer the mononuclear cell fraction to a clean tube & wash with PBS



seha Sf(PM)





Specimen Instructions

FFPE Specimens (Block or Slides)

DO NOT USE strong acids (e.g. hydrochloric acid, sulfuric acid, picric acid) as these destroy nucleic acid. When decalcification is required, the use of EDTA is recommended.

SAMPLE TYPE

1 FFPE BLOCK OR 16 UNSTAINED SLIDES (+ 1 H&E SLIDE)

Tissue should be formalin-fixed and embedded into a paraffin block. Use standard fixation methods with 10% neutral-buffered formalin. DO NOT use other fixatives (AZF, B5, Bouin's, Holland's). If sending slides, send 16 unstained slides (charged and unbaked, with tissue cut at a 5 micron thickness), plus 1 H&E slide.

SURFACE AREA

2 OPTIMUM: 5 × 5 mm²

Tissue should have a surface area of at least 25 mm² (5 x 5 mm², 2.5 x 10 mm²).



SURFACE VOLUME

3 OPTIMUM: 2 mm³


Optimal sample volume can be achieved by sending optimal tissue surface area (25 mm²) at a depth of ≥80 microns. For suboptimal tissue surface area, additional depth is required.

NUCLEATED CELLULARITY

4 DNA is extracted from nucleated cells. Samples with low nucleated cellularity (e.g., those with abundant mature erythrocytes, lesional cells that contain excessive cytoplasm, or tissue with extensive associated fibrosis) may require greater tissue volume to yield sufficient DNA at extraction.


5 MINIMUM: ≥20%

content is preferable.



Note for liver specimens: Higher tumor content may be required because hepatocyte nuclei have twice the DNA content of other somatic nuclei.






46 Optimizing specimen handling


Note: All cytologic and histologic specimens will be reviewed internally by a pathologist, and a determination of sample adequacy will be made. Additional or alternate material may be requested for optimal analysis.


Tissue sample handling for drug screening application

- Place tissue in a Petri dish and cover completely with PBS
- Cut tissue into small pieces (≥ 0.5 cm) with a scalpel
- Place tea strainer on an Erlenmeyer flask
- Place 3-4 pieces of chopped tissue into the sieve and push them through with a plunger (5mL syringe)
 - rinse with PBS
 - repeat until all tissue has been processed
- Filter the suspension through a 70µm cell strainer
- Centrifuge 100g for 10min at RM
- Resuspend pellet in warm media
- Filter the suspension once more
- Count cells and aliquot
- If extra cells freeze @ -80°C using Mr. Frosty



if shipping from other sites ship frozen cells on dry ice avoiding shipment on Fridays





Discussion points

Strategies for dealing with unforeseen delays or damaged shipments

Ensuring sample viability for cutting-edge tests

Importance of backup plans for specimen storage in case of equipment failures


Future trends in specimen handling

Can you share a case study or example where proper or improper handling significantly impacted specimen integrity?

What are the most common pitfalls in specimen handling, and what proactive steps can be taken to avoid them?

How can organizations prepare backup plans for specimen storage in the event of equipment failure or power outages?

What role does staff training play in mitigating risks related to specimen handling and shipping?



49 Optimizing specimen handling for precision medicine applications